The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | Updates in mesothelioma and small cell lung cancer at WCLC 2026
Dean Fennell, FRCP, PhD, FRSB, University of Leicester & University Hospitals of Leicester NHS Trust, Leicester, UK, provides his highlights from the 2026 World Conference on Lung Cancer congress, including results of the B7-H3-directed antibody-drug conjugate (ADC) in relapsed small cell lung cancer (SCLC). Dr Fennell also mentions presenting new data on a trial in progress for a PRMT5 inhibitor targeting MTAP deleted mesotheliomas, aiming to exploit synthetic lethality in this aggressive disease. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
